Beacon Therapeutics Holdings Ltd.

https://www.beacontx.com

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program currently being investigated for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. *

	Start	2022-10-18 established
	Group	Beacon Therapeutics (Group)
	Industry	gene therapy
	Industry 2	ophthalmic
	Person	Fellows, David (Beacon Therapeutics 202306 CEO formerly NightstaRx 201511 CEO)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	188 York Way Rolling Stock Yard
	City	N7 9AS London
	Tel	+44-203-3987880
		Address record changed: 2023-06-14

Basic data	Employees	n. a.

		* Document for »About Section«: Beacon Therapeutics Holdings Ltd.. (7/3/24). "Press Release: Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies". London & Cambridge, MA.

		Record changed: 2024-07-04

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Beacon Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)